A reckoning is coming for cash-strapped biotechs | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Friday
July 11, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
FRIDAY, JULY 11, 2025
A reckoning is coming for cash-strapped biotechs

Panorama

Chris Hughes, Bloomberg
21 January, 2022, 10:15 pm
Last modified: 21 January, 2022, 10:20 pm

Related News

  • JP Morgan sees 60% chance of global recession
  • Brac Bank, JP Morgan join hands for streamlined inward and outward remittances with Xpedite Select
  • JPMorgan to outsource $500 bln custody business in Hong Kong, Taiwan: sources
  • What India's inclusion in JPMorgan's bond index means for its markets
  • India gets green light to join JPMorgan bond index; rupee, bonds gain

A reckoning is coming for cash-strapped biotechs

As biotechs struggle to raise capital, buyers can afford to be picky: they have the upper hand

Chris Hughes, Bloomberg
21 January, 2022, 10:15 pm
Last modified: 21 January, 2022, 10:20 pm
A reckoning is coming for cash-strapped biotechs

The biotech sector is more than 40 percent down from its high last February, while the major pharmaceutical firms are flush with cash. That sounds like the ideal condition for dealmaking. But what if biotech boards and shareholders want takeover bids at yesterday's sky-high prices?

A 2020 study by JP Morgan Chase & Co. analysts found that when markets fall, a takeover target's one-year share-price high is a stubborn benchmark for pricing a deal. So it can take more than a year from a market correction until buyers and sellers align. Those dynamics may now be at work.

The first year of the pandemic saw a surge in stock-market enthusiasm for biotechnology as investors correctly bet that science would lead the world out of the pandemic. Moderna Inc.'s vaccine provided vindication. But the sector has now given up all its outperformance, and the market is looking beyond Covid-related breakthroughs. Bloomberg Intelligence analysts also point to concerns about drug-pricing pressure as well as a string of regulatory setbacks as factors damaging sentiment.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

Could the global mergers and acquisitions (M&A) boom bail out biotech investors with some juicy takeover offers? So far, M&A has benefited health-care investors pretty selectively. Last year saw a surge in deals for firms involved in medical equipment and services — diagnostics, face masks, hospitals and health insurance. One deal, the $34 billion leveraged buyout of family-owned Medline Industries Inc., represented a big chunk of the total. At the weekend, it emerged that Unilever Plc wants to buy GlaxoSmithKline Plc's consumer-healthcare business to get hold of brands like Sensodyne toothpaste.

The absence of a single really big transaction in pharmaceuticals and biotech in 2021 has created the impression of a lull when it comes to M&A in actual drug discovery. By contrast, the 2019 deal data in pharma and biotech were boosted by the $84 billion purchase of Allergan Ltd. and the $88 billion acquisition of Celgene Corp. In 2020, biotech Alexion Pharmaceuticals Inc. agreed to be bought for $39 billion. And 2018 saw the $81 billion bid for Shire Plc.

In reality, recent deal flow is stronger than it seems: The number of transactions over $1 billion has been pretty steady in pharma in recent years and has been growing in biotech. The question is whether biotech M&A could now markedly accelerate.

Falling share prices should tempt bargain hunters and deals are certainly affordable. Swiss drugmaker Novartis AG is looking for purchases up to around $10 billion. Pfizer Inc. is enjoying the revenue boost from its Covid vaccine. Sanofi has traditionally been a busy acquirer.

But biotech investors should temper their optimism. The message telegraphed by potential acquirers at JP Morgan Chase's annual healthcare conference last week was that buyers and sellers were some way apart on price.

That's more than just talking about their own book. Buyers can afford to be picky. After a deluge of recent listings, it's far from clear that biotechs can now raise capital in public or private markets so easily. Those that need cash face a reckoning. Buddying up with big pharma may be the only way to fund their ongoing R&D. Elsewhere, acquisitive bosses may find decent opportunities among unlisted biotechs that may now struggle to do an initial public offering or blank-check merger. After all, without a quoted share, they are less likely to be hostage to an unrealistic anchor price.

Disclaimer: This article first appeared on Bloomberg, and is published by special syndication.

Biotech / JP Morgan

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Abul Barkat at Dhaka Metropolitan Magistrate Court on 11 July 2025. Photo: TBS
    Economist Abul Barkat sent to jail in Tk297cr embezzlement case
  • BNP senior leader Salahuddin Ahmed. Photo: Collected
    No scope for electoral alliance with Jamaat, door not closed for NCP: BNP's Salahuddin
  • Sketch: TBS
    No peace through concession — only struggle secures tomorrow

MOST VIEWED

  • Photo: Mohammad Minhaj Uddin/TBS
    SSC, equivalent results: Pass rate drops to 68.45%, GPA-5 also declines
  • In terms of stream of education, girls maintained their excellence as well. Photo: TBS
    SSC 2025: Girls dominate boys by over 5%
  • Govt vehicle purchase, foreign trip, new building construction banned: Finance ministry
    Govt vehicle purchase, foreign trip, new building construction banned: Finance ministry
  • Students sit for SSC exam at Motijheel Girls' High School on 10 April 2025. Photo: Mehedi Hasan/TBS
    SSC exam results out: Here's how you can check online and via SMS
  • The overall pass rate across all boards this year, 68.45%, is significantly lower than last year's. Photo: Focus Bangla
    SSC 2025: Rajshahi board records highest pass rate, Barishal lowest
  • Representational image. Photo: Collected
    35% tariff: Bangladesh, US 'agree on most issues' as first day of talks ends

Related News

  • JP Morgan sees 60% chance of global recession
  • Brac Bank, JP Morgan join hands for streamlined inward and outward remittances with Xpedite Select
  • JPMorgan to outsource $500 bln custody business in Hong Kong, Taiwan: sources
  • What India's inclusion in JPMorgan's bond index means for its markets
  • India gets green light to join JPMorgan bond index; rupee, bonds gain

Features

Photo: Collected/BBC

What Hitler’s tariff policy misfire can teach the modern world

20h | The Big Picture
Illustration: TBS

Behind closed doors: Why women in Bangladesh stay in abusive marriages

23h | Panorama
Purbachl’s 144-acre Sal forest is an essential part of the area’s biodiversity. Within it, 128 species of plants and 74 species of animals — many of them endangered — have been identified. Photo: Syed Zakir Hossain/TBS

A forest saved: Inside the restoration of Purbachal's last Sal grove

23h | Panorama
Photo: Rajib Dhar/TBS

11 July 2024: Riot vehicles, water cannons hit the streets as police crack down on protesters

16h | Panorama

More Videos from TBS

Threat of 35 percent tariff on Canadian goods

Threat of 35 percent tariff on Canadian goods

37m | TBS World
Israel ready to strike back if Iran threatens: Katz

Israel ready to strike back if Iran threatens: Katz

2h | TBS World
India is strengthening ties with Israel

India is strengthening ties with Israel

3h | TBS World
'Hypocrisy' will not continue, Iran tells IAEA

'Hypocrisy' will not continue, Iran tells IAEA

19h | TBS World
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net